When was ni2o founded?

ni2o was founded in 2017 and raised its 1st funding round 4 years after it was founded.

Where is ni2o located?

ni2o is headquartered in Mclean, United States.

How many employees does ni2o have?

As of Sep 30, 2026, the latest employee count at ni2o is 10.

Is ni2o a funded company?

ni2o is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Apr 27, 2021.

When was the latest funding round of ni2o?

ni2o's latest funding was a $***** Conventional Debt round on May 18, 2021, with participation from 0 investor.

Where does ni2o rank among its competitors?

ni2o ranks 13th amongst 62 active competitors, of which 15 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Cala Health, which secured $50M in Apr, 2026.

Who are the top competitors of ni2o?

ni2o's top competitors include Cala Health, Encora Therapeutics and Aleva Neuro. Among them, Cala Health secured the most recent funding round in April, 2026.

ni2o - 2026 Company Profile, Team, Funding & Competitors

ni2o is a funded company based in Mclean (United States), founded in 2017 by Newton Howard. It operates as an AI-driven brain-computer interface chip. ni2o has raised an undisclosed amount in funding. The company has 62 active competitors, including 15 funded and 2 that have exited. Its top competitors include companies like Cala Health, Encora Therapeutics and Aleva Neuro.

Company Details

NI2O is developing an AI-driven brain-computer interface. The company is developing Kiwi, a chip (size of rice grain) which can be implanted in the brain via the nasal cavity. The chip interacts with neurons using light and electrical impulses and will be used to treat neurological disorders, degenerative diseases, and cognitive enhancement. The company is in the stealth mode and looking for investors and partners as of June 2018.

Website: ni2o.com
Social
Email ID: *****@ni2o.com

Key Metrics

Founded Year

2017

Location

Mclean, United States

Stage

Funding Raised

Latest Funding Round

Conventional Debt, May 18, 2021, $*****

Investors

Oxford University Innovation & 1 more

Ranked

13^th among 62 active competitors

Employee Count

10 as on Sep 30, 2026

Similar Companies

Cala Health & 73 more

View ni2o's full profile

ni2o has raised funding over 2 rounds. Its first funding round was on Apr 27, 2021. ni2o has 2 institutional investors.

Here is the list of recent funding rounds of ni2o:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 18, 2021	9964679	Conventional Debt	7404653	1515893	2624853	7550686
Apr 27, 2021	7272817	Conventional Debt	6403984	1359281	3499362	3799784

Access funding benchmarks and valuations. Sign up today!

View details of ni2o's funding rounds and investors

The founders of ni2o is Newton Howard. Russ Hayward is the CEO of ni2o.

Here are the details of ni2o's key team members:

Newton Howard: Founder of ni2o and founder of 6 other companies, including Howard Brain Sciences Foundation, C4ADS and Q-Bank.
Contact Info: 1 email address
Russ Hayward: CEO of ni2o.

View details of ni2o's Founder profiles and Board Members

ni2o's employee count trend

ni2o has 10 employees as of Sep 26. Here is ni2o's employee count trend over the years:

Uncover ni2o's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ni2o include Cala Health, Encora Therapeutics and Aleva Neuro. Here is the list of Top 10 competitors of ni2o, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cala Health 2013, Stanford (United States), Series D	Developer of a wearable non-invasive neuromodulation device	$257M	Vertex Growth, Novartis & 29 others	63/100
2nd	Encora Therapeutics 2018, Cambridge (United States), Seed	Developer of smart devices for the treatment of neurological movement disorders	$1.5M	Innospark Ventures, SDX Energy & 2 others	53/100
3rd	Aleva Neuro 2008, Lausanne (Switzerland), Series E	Develops implantable deep brain stimulation systems that enables therapies for neurological diseases	$57M	CIP Merchant Capital, Venture Kick & 11 others	47/100
4th	InBrain Pharma 2018, Paris (France), Seed	Developer of therapeutic solutions for the treatment of neurodegenerative diseases	$3.15M	Finovam Gestion, Nord France Amorquage	46/100
5th	Kinetikos Health 2015, Lisbon (Portugal), Seed	Digital platform to assist healthcare providers and patients in the management of Parkinson’s disease	$1.11M	Europa, BGI	46/100
6th	Civitas Therapeutics 2009, Chelsea (United States), Acquired	Pulmonary delivery therapies for relief from intermittent debilitating motor fluctuations	$128M	Partner Fund Management, Rock Springs Capital ... & 12 others	45/100
7th	PhotoPharmics 2011, American Fork (United States), Series B	Developer of non-invasive phototherapy for Parkinson's disease	$45.7M	Kickstart Fund, Frazier Group & 6 others	43/100
8th	NeuroRPM 2017, Washington, DC (United States), Funding Raised	Provider of AI-powered remote monitoring app for Parkinson’s disease	-	-	43/100
9th	NDI Medical 2002, Cleveland (United States), Series A	Neurodevice venture capital firm developing innovative technologies for neurological function restoration	$2.11M	Military Health, HHS & 1 others	43/100
10th	Sapiens Neuro 2011, Munich (Germany), Acquired	Developer of brain stimulation device to treat neurodegenerative disorders	$55.9M	Wellcome Trust, Life Sciences Partners & 5 others	42/100
13th	ni2o 2017, Mclean (United States), Funding Raised	AI-driven brain-computer interface chip	-	Oxford University Innovation, Caplin Ventures	37/100